Neoplasia lect 5

Insensitivity to Growth-Inhibitory Signals

- The signal of tumor suppressor genes have anti-growth signals that can prevent cell proliferation in different mechanisms:
- **1. May cause dividing cells to enter G0 (quiescence)**
- 2. May cause the re-entery of cells in a postmitotic, differentiated pool and lose replicative potential.

<u>Retinoblastoma gene (RB): Governor of the Cell</u> <u>Cycle</u>

- RB gene is a key negative regulator of the cell cycle, is directly or indirectly inactivated in most human cancers.
- Retinoblastoma (*RB*) gene, the first and prototypic cancer suppressor gene to be discovered.

- Retinoblastoma (RB) gene, the first and prototypic cancer suppressor gene to be discovered.
- Retinoblastoma is an uncommon childhood tumor.
- Approximately 60% of retinoblastomas are sporadic, and 40% are familial.
- The predisposition to develop the tumor being transmitted as an autosomal dominant trait.

 To account for the sporadic and familial occurrence of an identical tumor, Knudson, in 1974, proposed his now famous *two-hit* hypothesis.

- Two mutations (hits) are required to produce retinoblastoma.
- These involve the *RB* gene, located on chromosome 13q14.
- Both of the normal alleles of the *RB* locus must be inactivated (two hits) for the development of retinoblastoma.

- In familial cases, children inherit one defective copy of the *RB* gene in the germ line while the other copy is normal.
- Retinoblastoma develops when the normal *RB* gene is lost in retinoblasts as a result of somatic mutation.

- In retinoblastoma families only a single somatic mutation is required for expression of the disease
- The familial transmission follows an autosomal dominant inheritance pattern.
- In sporadic cases, both normal *RB* alleles are lost by somatic mutation in one of the retinoblasts.
- A retinal cell that has lost both of the normal copies of the *RB* gene becomes cancerous

- Although the loss of normal *RB* genes was discovered initially in retinoblastomas, it is now evident that homozygous loss of this gene is a fairly common event in several tumors including :
- Breast cancer
- Small-cell cancer of the lung
- Bladder cancer.

• Patients with familial retinoblastoma also are at greatly increased risk of developing osteosarcomas and some soft tissue sarcomas.



© Elsevier. Kumar et al: Robbins Basic Pathology 8e - www.studentconsult.com

• The function of the RB protein is to regulate the G1/S checkpoint, the portal through which cells must pass before DNA replication commences.

• The transition from G1 to S is an extremely important checkpoint in the cell cycle

RB Gene and Cell Cycle

- The *RB* gene product is a DNA-binding protein that is expressed in every cell type examined
- It exists in an *active hypophosphorylated* and an inactive hyperphosphorylated state.
- The importance of RB lies in its enforcement of G₁, or the gap between mitosis (M) and DNA replication (S).

- In embryos, cell divisions proceed with DNA replication beginning immediately after mitosis ends.
- However, as development proceeds, two gaps are incorporated into the cell cycle:
- 1-Gap 1 (G₁) : between mitosis (M) and DNA replication (S)
- 2-Gap 2 (G₂) : between DNA replication (S) and mitosis (M)

- Although each phase of the cell cycle circuitry is monitored carefully
- the transition from G₁ to S is believed to be an extremely important checkpoint in the cell cycle clock.
- Once cells cross the G₁ checkpoint they can pause the cell cycle for a time, but they are obligated to complete mitosis.

- In G₁cells can exit the cell cycle :
- 1- Temporarily, called quiescence
- 2- Permanently, called senescence.
- In G₁, therefore, diverse signals are integrated to determine whether the cell should enter the cell cycle, exit the cell cycle and differentiate, or die.
- RB is a key factor in this decision process.



© Elsevier. Kumar et al: Robbins Basic Pathology 8e - www.studentconsult.com

The initiation of DNA replication requires the activity of cyclin E/CDK2 complexes, and expression of cyclin E is dependent on the E2F family of transcription factors.

 Early in G₁, RB is in its hypophosphorylated active form and it binds to and inhibits the E2F family of transcription factors preventing transcription of cyclin E.

- Hypophosphorylated RB blocks E2F-mediated transcription in at least two ways :
- 1- it sequesters E2F, preventing it from interacting with other transcriptional activators.
- 2- RB recruits chromatin remodeling proteins, such as histone deacetylases and histone methyltransferases, which bind to the promoters of E2F-responsive genes such as cyclin E.
- These enzymes modify chromatin at the promoters to make DNA insensitive to transcription factors.

- This situation is changed upon mitogenic signaling.
- Growth factor signaling leads to cyclin D expression and activation of cyclin D-CDK4/6 complexes.
- These complexes phosphorylate RB inactivating the protein and releasing E2F to induce target genes such as cyclin E.
- Expression of cyclin E then stimulates DNA replication and progression through the cell cycle.

• When the cells enter S phase, they are committed to divide without additional growth factor stimulation.

• During the ensuing M phase, the phosphate groups are removed from RB by cellular phosphatases, regenerating the hypophosphorylated (active) form of RB.

- E2F is not the sole target of RB.
- The versatile RB protein has been shown to bind to a variety of other transcription factors that regulate cell differentiation.

• E.g

RB stimulates myocyte-, adipocyte-, melanocyte-, and macrophagespecific transcription factors.

- RB pathway is important to :
- 1- Control of cell cycle progression at G₁
- 2- Induce cell differentiation
- **3- Induce senescence**

- Mutations in other genes that control RB phosphorylation can mimic the effect of RB loss
- Genes are mutated in many cancers that seem to have normal *RB* genes.

- E.g
- Mutational activation of CDK4 or overexpression of cyclin D would favor cell proliferation by facilitating RB phosphorylation and inactivation.
- Cyclin D is overexpressed in many tumors because of gene amplification or translocation.
- Mutational inactivation of CDKIs also would drive the cell cycle by unregulated activation of cyclins and CDKs.

• Simian virus 40 and polyomavirus large-T antigens, adenovirus EIA protein, and human papillomavirus (HPV) E7 protein all bind to the hypophosphorylated form of RB.

 The RB protein, unable to bind to the E2F transcription factors, is functionally deleted, and the cells lose the ability to be inhibited by antigrowth signals.

p53 Gene: Guardian of the Genome

- The *p53* tumor suppressor gene is one of the most commonly mutated genes in human cancers.
- P53 induces neoplastic transformation by three interlocking mechanisms:
- 1-Activation of temporary cell cycle arrest (termed quiescence),
- 2-Induction of permanent cell cycle arrest (termed senescence),
- 3-Triggering of programmed cell death (termed apoptosis).

- *p53* can be viewed as a central monitor of stress, directing the stressed cells toward an appropriate response.
- A variety of stresses can trigger the *p53* response pathways including :
- 1-Anoxia
- 2-Inappropriate oncogene expression (e.g., MYC or RAS),
- **3-Damage to the integrity of DNA.**

In nonstressed healthy cells p53 has a short half-life (20 minutes) because of its association with MDM2, a protein that targets it for destruction.

- When the cell is stressed for example by an assault on its DNA p53 undergoes post-transcriptional modifications that release it from MDM2 and increase its half-life.
- During the process of being unshackled from MDM2, p53 also becomes activated as a transcription factor.

Dozens of genes whose transcription is triggered by p53 have been found.

- They can be grouped into two broad categories:
- 1-those that cause cell cycle arrest
- 2-those that cause apoptosis.

 If DNA damage can be repaired during cell cycle arrest, the cell reverts to a normal state; if the repair fails, p53 induces apoptosis or senescence.

• The manner in which p53 senses DNA damage and determines the adequacy of DNA repair are not completely understood.

- The key initiators of the DNA-damage pathway are two related protein kinases:
- 1-ataxia-telangiectasia mutated (ATM).
- 2-ataxia-telangiectasia mutated related (ATR).

Patients with this disease, which is characterized by an inability to repair certain kinds of DNA damage, suffer from an increased incidence of cancer.

- The types of damage sensed by ATM and ATR are different, but the down-stream pathways they activate are similar.
- Once triggered, both ATM and ATR phosphorylate a variety of targets, including p53 and DNA repair proteins.
- Phosphorylation of these two targets leads to a pause in the cell cycle and stimulation of DNA repair pathways respectively.

- p53-mediated cell cycle arrest may be considered the primordial response to DNA damage .
- It occurs late in the G₁ phase and is caused mainly by *p53*-dependent transcription of the CDKI *CDKN1A (p21)*.
- The CDKN1A gene inhibits cyclin-CDK complexes and prevents phosphorylation of RB essential for cells to enter G₁ phase.
- Such a pause in cell cycling gives the cells time to repair DNA damage.

- p53 also helps the process by inducing certain proteins, such as GADD45 (growth arrest and DNA damage), that help in DNA repair.
- If DNA damage is repaired successfully, p53 up-regulates transcription of MDM2, leading to destruction of p53 and relief of the cell cycle block.
- If the damage cannot be repaired, the cell may enter p53-induced senescence or undergo p53-directed apoptosis

- more than 70% of human cancers have a defect in this gene, and the remaining malignant neoplasms have defects in genes up-stream or down-stream of *p53*.
- Homozygous loss of the *p53* gene is found in virtually every type of cancer, including :
- 1-carcinomas of the lung,
- 2-carcinoma of colon,
- 3-carcinoma of breast .

• Less commonly, some individuals inherit a mutant *p53* allele; this disease is called the *Li-Fraumeni syndrome*.

 inheritance of one mutant allele predisposes individuals to develop malignant tumors because only one additional hit is needed to inactivate the second, normal allele.

Patients with the *Li-Fraumeni syndrome* have a 25 X greater chance of developing a malignant tumor by age 50 compared with the general population.

- In contrast to patients who inherit a mutant RB allele, the spectrum of tumors that develop in patients with the Li-Fraumeni syndrome is varied
- The most common types of tumors are: sarcomas, breast cancer, leukemia, brain tumors, and carcinomas of the adrenal cortex.